Stifel Nicolaus analyst Jonathan Block reiterated a Hold rating on Glaukos (NYSE: GKOS) yesterday and set a price target of $35. The company’s shares closed yesterday at $45.01, close to its 52-week high of $46.50.
According to TipRanks.com, Block is a 5-star analyst with an average return of 24.0% and a 77.7% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Align Tech.
Currently, the analyst consensus on Glaukos is a Moderate Buy with an average price target of $42.
See today’s analyst top recommended stocks >>
Based on Glaukos’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $2.71 million. In comparison, last year the company had a GAAP net loss of $3.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway.
